Resources and forms for every step along the way

Select and download resources for LEQVIO®

Select all resources below

Enrollment

Start Form

Download Download

Start Form - Spanish

Download Download

Patient Consent Form

Download Download

Patient Consent Form - Spanish

Download Download

Service Center Portal Overview

Download Download

Patient Coverage

Prior Authorization & Appeals Guide

Download Download

Letter of Medical Necessity Checklist

Download Download

Sample Letter of Medical Necessity

Download Download

Letter of Medical Exception Checklist

Download Download

Sample Letter of Medical Exception

Download Download

Letter of Appeal Checklist

Download Download

Sample Letter of Appeal

Download Download

Financial Support

Patient Co-pay Checklist

Download Download

Provider Co-pay Checklist

Download Download

Co-pay Flashcard

Download Download

Co-pay Portal Overview

Download Download

Patient and Provider Co-pay Claim Form

Download Download

Specialty Pharmacy Commercial Co-pay Claim Form

Download Download

Acquisition

LEQVIO Prescription Considerations

Download Download

Buy-and-Bill 5 Step Guide

Download Download

Buy-and-Bill Checklist

Download Download

Distribution & Acquisition Flashcard

Download Download

Alternate Site of Care Referral Guide

Download Download

Alternate Site of Care Referral/Order Form

Download Download

Alternate Site of Care Clinical Documentation Referral
Checklist

Download Download

LEQVIO Patient Tracker

Download Download

LEQVIO Patient Management Tracker & Instructions for Use

Download Download

LEQVIO Therapy Plan - Epic EHR

Download Download

Reimbursement

Billing & Coding Guide

Download Download

Claim Filing Checklist

Download Download

Annotated CMS-1500 Form

Download Download

Annotated CMS-1450 (UB-04) Form

Download Download

IMPORTANT SAFETY INFORMATION
AND INDICATION

Expand Collapse

IMPORTANT SAFETY INFORMATION

LEQVIO is contraindicated in patients with a prior serious hypersensitivity reaction to inclisiran or any of the excipients in LEQVIO. Serious hypersensitivity reactions have included angioedema. Adverse reactions in clinical trials (≥3% of patients treated with LEQVIO and more frequently than placebo) were injection site reaction, arthralgia, and bronchitis.

Please click here for LEQVIO full Prescribing Information.

INDICATION

LEQVIO (inclisiran) injection is indicated as an adjunct to diet and statin therapy for the treatment of adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), to reduce low-density lipoprotein cholesterol (LDL-C).

Please click here for LEQVIO full Prescribing Information.